CEP
MCRB icon

Chicago Equity Partners’s Seres Therapeutics MCRB Stock Holding History

Chicago Equity Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,011
Closed -$154K – 846
2018
Q3 		$154K Sell
1,011
-1,404
-58% -$227K ﹤0.01% 787
2018
Q2 		$415K Buy
+2,415
New +$395K 0.01% 682

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Chicago Equity Partners's MCRB Position: Q4 2018 in Review

Chicago Equity Partners sold out of Seres Therapeutics (MCRB) in Q4 2018, closing a stake of 1,011 shares — an estimated $154K sold.

Chicago Equity Partners first reported a position in MCRB in Q2 2018 and held it in 2 quarters. The position peaked at $415K in Q2 2018. 70 funds tracked by Wall St. Rank hold MCRB as of Q4 2018.

  • Chicago Equity Partners reported no remaining Seres Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 1,011 Seres Therapeutics shares in Q4 2018, an estimated $154K.
  • Chicago Equity Partners first reported a position in Seres Therapeutics in Q2 2018 and held it in 2 quarters.
  • Chicago Equity Partners's Seres Therapeutics position peaked at $415K in Q2 2018.
  • 70 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2018.

Based on Chicago Equity Partners's 13F filing for Q4 2018, filed 5 Feb 2019.